memantine / Generic mfg. - LARVOL DELTA

"Unveiling Alzheimer's Disease (1901-2025): Historical Insights, Global Burden, Biological Mechanisms, Diagnostics, And Therapeutic Strategies". (PubMed, Ageing Res Rev) - "Therapeutically, the landscape has shifted from symptomatic treatments (e.g., cholinesterase inhibitors, memantine) to disease-modifying agents. Recent FDA approvals of monoclonal antibodies like Aducanumab, Lecanemab, and Donanemab mark a new era in targeted immunotherapy...Emerging drug delivery systems, including nanocarriers and intranasal formulations, aim to overcome the BBB and enhance therapeutic efficacy. The manuscript emphasizes the urgent need for integrative, personalized, and scalable solutions to manage AD's growing burden."

IO biomarker • Journal • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Mental Retardation • Psychiatry

Combined Preventive and Preconditioning Treatments for the Comorbidity of Alzheimer's Disease and Ischemic Stroke in a GluN3A Knockout Mouse and a 5xFAD Mouse. (PubMed, Cells) - "In the preclinical stage of 3-month-old GluN3A KO mice, an NMDAR-mediated sporadic AD model, and 5xFAD mice, an amyloid-based familial AD model, treatments with memantine (MEM), an NMDAR antagonist (10 mg/kg/day in drinking water) and a drug-free control were started when cognition of these mice was generally normal...This is the first report endorsing a shared mechanism of NMDAR hyperactivity in AD and stroke in AD models with distinctive risk factors. The dual therapeutic effects of the preemptive MEM treatment provide a disease-modifying possibility for individuals who are susceptible to sporadic or familial AD as well as ischemic stroke."

Journal • Preclinical • Alzheimer's Disease • Cardiovascular • CNS Disorders • Inflammation • Ischemic stroke • Vascular Neurology

The patient pathway in the diagnosis and treatment of mild cognitive impairment and new therapeutic opportunities. Resolution of the Expert Council (Moscow, April 21, 2025) (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "Bogolepova discussed the use of the combination of melatonin 3 mg+memantine 5 mg, registered in the RF for the treatment of mild and moderate CI...Following the session, the moderators presented the participants with a draft resolution, which was revised according to comments and suggestions received. The final version of the resolution, published below, was approved by all members of the council."

Journal • CNS Disorders • Cognitive Disorders • Dementia • Inflammation • Sleep Disorder

Real-world analysis of medication adherence and cost of care for comorbid conditions in patients with early Alzheimer's disease in the U.S. (PubMed, Neurodegener Dis Manag) - "DPP-4 inhibitors had the highest medication adherence rate (66.67% of patients), and memantine had the lowest (39.13% of patients)...Patients with early AD had multiple comorbidities and took multiple medications. Suboptimal medication adherence and high healthcare costs were observed."

HEOR • Journal • Real-world evidence • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Memantine as an Adjuvant in Cognitive Symptoms of Schizophrenia with a Chronic Course: A Follow-up Study. (PubMed, Indian J Psychol Med) - "The results of this study suggest that adding memantine to an antipsychotic treatment regimen may provide beneficial effects on cognitive symptoms in chronic schizophrenia, with good tolerability and minimal adverse effects. The study was registered under the Clinical Trials Registry in India (CTRI), CTRI/2024/12/077774."

Journal • CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia

Inhba, Homer1 and Bdnf are major targets of transcriptomic dysregulation by neurodegenerative disease-associated excitotoxic NMDA receptor signaling. (PubMed, Commun Biol) - "In a Huntington's disease (HD) mouse model, treatment with memantine or targeting the NMDAR/TRPM4 complex with FP802 restored gene expression, notably Inhba, Homer1 and Bdnf, and attenuated the decrease of the HD disease marker Ppp1r1b (DARPP-32). These findings identify esNMDAR-driven transcriptional dysregulation as a key pathomechanism in neurodegenerative disease, supporting inhibition of esNMDAR-signaling as a promising therapeutic approach."

Journal • CNS Disorders • Huntington's Disease • Movement Disorders • ATF3 • BTG2 • EGR1 • MIR132

Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia (clinicaltrials.gov) - P3 | N=450 | Recruiting | Sponsor: Bigespas LTD

New P3 trial • Alzheimer's Disease • CNS Disorders • Dementia

Treatment patterns of symptomatic treatments for Alzheimer's disease and related dementias. (PubMed, BMC Geriatr) - No abstract available

Journal • Alzheimer's Disease • CNS Disorders • Dementia

Establishment of UPLC-MS/MS Method for Determining the Content of Memantine in Rat Plasma and Its Pharmacokinetic Differences at Different Altitudes. (PubMed, Biomed Chromatogr) - "In conclusion, high-altitude hypoxia significantly affects MM metabolism in rats, potentially posing a risk of drug accumulation in plasma. The research findings provide a reference for the rational use of MM in high-altitude regions."

Journal • PK/PD data • Preclinical

Behavioral Treatment and Memantine in Body Focused Repetitive Behaviors (clinicaltrials.gov) - P2/3 | N=26 | Active, not recruiting | Sponsor: University of Chicago | Trial completion date: Dec 2025 ➔ Jun 2026 | Trial primary completion date: Dec 2025 ➔ Jun 2026

Trial completion date • Trial primary completion date

Neurobiotech innovative strategies targeting Alzheimer's disease through therapeutic micro and macroalgae potentials. (PubMed, J Neuroimmunol) - "Current therapeutic approaches primarily focus on alleviating symptoms through drugs such as donepezil and memantine...This review aims to bridge the fields of neurobiotechnology and marine bioresources by examining the synergistic potential of algal compounds and gene-editing strategies in combating Alzheimer's disease. Algal-derived compounds are utilized in pharmaceuticals, nutraceuticals, and dietary supplements, and may offer neuroprotective benefits that could aid in the prevention or treatment of AD.By integrating insights from molecular biology, pharmacology, and genomics, we seek to illuminate a novel, multidisciplinary framework for future therapeutic innovation."

Journal • Alzheimer's Disease • CNS Disorders • Inflammation

GRIN2A alterations in primary CNS neoplasms: a case series (SNO 2025) - "Five patients received memantine over the course of their treatment for other indications, 1 ketamine, and 1 riluzole (for comorbid amyotrophic lateral sclerosis). GRIN2A alterations represent unique alterations in a subset of primary brain tumors. Analysis is ongoing regarding survival, functional significance, and presence of co-occurring somatic alterations."

Clinical • Tumor mutational burden • Amyotrophic Lateral Sclerosis • Brain Cancer • CNS Disorders • CNS Tumor • Melanoma • Solid Tumor • CDKN2A • GRIN2A • MGMT • MSH6 • TMB

The NMDA Receptor Antagonist Memantine Modulates Aging and Stress Resilience. (PubMed, Aging Cell) - "Memantine, but not ketamine, extends median lifespan and reproductive lifespan, suggesting that the observed effects are not shared with ketamine at the tested concentration. Functionally, memantine was found to reduce mitochondrial and oxidative stress, while enhancing β-oxidation of fatty acids, and modifying behavioral responses to food cues, delaying food-seeking behavior and increasing locomotion under starvation, without affecting lipid storage. In summary, these findings suggest that memantine promotes stress resilience and healthy aging via metabolic changes that overlap with CR-associated pathways, highlighting its potential as a longevity-modulating intervention."

Journal • Metabolic Disorders

Combined adjunctive Perampanel and Memantine with standard of care chemoradiotherapy in newly diagnosed glioblastoma patients led to longer adjuvant treatment and prolonged functional independence: a single institution case series (SNO 2025) - "Historically, 47% of glioblastoma patients completed six cycles of adjuvant temozolomide. At 10 months, 5/8 (62.5%) maintained KPS>60, with 4/8 (50%) MGMT unmethylated patients sustaining KPS>90 for over 6 months. Conclusions : Adding perampanel and memantine to standard chemoradiotherapy may extend chemotherapy treatment duration and prolong functional independence in both MGMT unmethylated and methylated glioblastoma patients, potentially improving overall outcomes."

Clinical • Brain Cancer • Glioblastoma • Glioma • Solid Tumor • MGMT

An Initial Report of Memory Avoidance Whole Brain Radiotherapy to Treat Brain Metastases: A Prospective Phase 2 Trial (SNO 2025) - P2 | "Further evaluation of the delayed impact (> 6 months) of MA-WBRT on cognitive function will be reported when data are available. A direct comparison of MA-WBRT plus memantine vs. HA-WBRT plus memantine is forthcoming in a randomized phase 2 trial."

Clinical • P2 data • Solid Tumor

Synergistic antimigraine effects of lisinopril and memantine associated with an improved therapeutic index (EHF-EHC 2025) - "Lisinopril and memantine exhibit strong pharmacodynamic synergy in migraine models without adverse or amplifying cardiovascular effects. This combination may offer enhanced efficacy with a favourable side effect profile, supporting its potential utility in migraine prophylaxis."

Cardiovascular • CNS Disorders • Migraine • Pain

Arc-mediated synaptic plasticity regulates cognitive function in a migraine mouse model (EHF-EHC 2025) - "C57BL/6 mice were randomly divided into four groups: the IS group (migraine model induced by inflammatory soup, IS), IS+M group (IS model + memantine treatment), IS+S group (IS model + sumatriptan treatment), and a control group (PBS with no IS stimulation). Cognitive dysfunction in the migraine model was associated with impaired synaptic plasticity, as indicated by reduced Arc expression. Memantine treatment alleviated cognitive deficits and restored synaptic function, suggesting that Arc-mediated synaptic plasticity may play a critical role in migraine-related cognitive impairment and could be a potential therapeutic target."

Preclinical • ADHD (Impulsive Aggression) • Alzheimer's Disease • Attention Deficit Hyperactivity Disorder • CNS Disorders • Cognitive Disorders • Migraine • Pain

Comparative efficacy and safety of symptomatic therapy and disease-modifying therapy for Alzheimer's disease: a systematic review and network meta-analysis. (PubMed, Front Neurosci) - "Aducanumab significantly improved ADAS-cog scores compared with placebo (MD -5.97, 95%CI -10.33, -1.61; SUCRA: 93.0%) and demonstrated notable improvements in ADCS-ADL scores (MD 4.99, 95%CI 2.27, 7.72; SUCRA: 98.6%). Memantine ranked highest for neuropsychiatric symptoms (SUCRA: 80.8%)...Lecanemab provides moderate benefits, while donanemab appears less effective. Thus, clinicians should apply disease-modifying therapies cautiously and individually, carefully balancing potential risks and benefits for each patient. PROSPERO [CRD42025637730], https://www.crd.york.ac.uk/PROSPERO/."

Journal • Retrospective data • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Psychiatry

Memantine, an NMDA Receptor Antagonist, Attenuates Doxorubicin-Induced Cardiac Oxidative Stress and Inflammation in Mouse 4T1 Breast Cancer Model. (PubMed, Breast Cancer (Auckl)) - "TUNEL test revealed that the memantine + doxorubicin group demonstrated significantly more tumor cell apoptosis than the mice in other groups (P-value < 0.05), although tumor volume reduction was not significantly greater than that in the doxorubicin group. This study is the first to demonstrate that memantine can enhance the therapeutic efficacy of doxorubicin chemotherapy while also reducing doxorubicin-induced cardiac oxidative stress and inflammation in a breast cancer model."

Journal • Preclinical • Breast Cancer • Cardiovascular • Oncology • Solid Tumor • MPO • TNFA

Assessment of Ultrasonic Vocalization-Mediated Communication Deficits in AD Rats: A Social Learning Paradigm Using Conspecific Drinking Behavior. (PubMed, Behav Processes) - "This study reveals AD rats' abnormal USV characteristics, preliminarily lays an experimental basis for an evaluation method combining USVs and drinking behavior, provides a new non-invasive, low-cost perspective for assessing AD rats' behavioral phenotypes, and verifies this method correlates with traditional cognitive evaluation (Morris water maze) and can effectively reflect the improvement of AD behavioral phenotypes after memantine intervention."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders

Dynamic associations of cholinesterase inhibitors and memantine with cognitive trajectories in individuals with Alzheimer's or mixed dementia: a real-world analysis using the quality registry SveDem. (PubMed, Alzheimers Res Ther) - No abstract available

Journal • Real-world evidence • Alzheimer's Disease • CNS Disorders • Dementia

Baseline Neuropsychological Characteristics of Adolescents and Young Adults with Down Syndrome Who Participated in Two Clinical Trials of the Drug Memantine. (PubMed, Brain Sci) - "This study demonstrated remarkable consistency of results across studies in two countries with significantly different cultures and levels of socioeconomic development, which provides supporting evidence for the future design and implementation of similar multicenter, international clinical studies involving participants with DS."

Journal • Alzheimer's Disease • CNS Disorders • Developmental Disorders • Genetic Disorders

High-Risk Prescribing in Older People With and Without Dementia in Australia: A Nationwide Cross-Sectional Study. (PubMed, J Am Med Dir Assoc) - "High-risk prescribing is common in those living with dementia and varies by sociodemographic factors. Regular, targeted medication reviews are needed to ensure quality use of medicines in this population."

Journal • Observational data • CNS Disorders • Dementia

Dementia as a major comorbidity in late-onset epilepsy. (PubMed, Epileptic Disord) - "They were more likely to have depression (p = .04) and were more frequently treated with acetylcholine esterase inhibitors and memantine before the diagnosis of epilepsy (p"

Journal • CNS Disorders • Dementia • Depression • Dyslipidemia • Epilepsy • Hypertension • Metabolic Disorders • Psychiatry

Modulation of Lingo-1 and NMDA receptor expression by memantine and vitamin D3 co-therapy attenuates motor and non-motor symptoms in essential tremor. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Memantine and vitD3 combination therapy ameliorates both motor and non-motor symptoms in a mouse model of ET through modulation of Lingo-1 and NMDA receptor expression pathways. These findings suggest that this combination approach represents a therapeutic strategy that addresses the complex pathophysiology of ET while providing neuroprotective benefits."

Journal • Essential Tremor • Movement Disorders